Join to View Full Profile
600 Highland AveMadison, WI 53792
Phone+1 608-263-7022
Fax+1 608-266-6020
Dr. Chang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2005 - 2007- University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2003 - 2005
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2000 - 2003
Indiana University School of MedicineClass of 2000
Certifications & Licensure
WI State Medical License 2001 - 2025
IL State Medical License 2007 - 2011
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
- Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Start of enrollment: 2009 Oct 01
- Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
- Join now to see all
Publications & Presentations
PubMed
- Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphom...Julie E Chang, Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre
Clinical Lymphoma, Myeloma & Leukemia. 2025-03-01 - 1 citationsHigh-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.Narendranath Epperla, Adam S Zayac, Daniel J Landsburg, Allison M Bock, Grzegorz S Nowakowski
Blood Advances. 2024-10-22 - Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and ...Julie E Chang, Tuo Wang, KyungMann Kim, Matthew Folstad, Mariah Endres
Leukemia & Lymphoma. 2024-10-01
Press Mentions
VcR-CVAD Yields High Responses, ‘Excellent’ Survival in MCLJanuary 11th, 2018
Will Maintenance Lenalidomide Become A Standard for Relapsed CLL?November 2nd, 2017
Wisconsin Cancer Patients Test Encouraging Lymphoma TreatmentDecember 23rd, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
